Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077226 | 0.91 | HTT (0.41) | HTTMEN1KMT2AL3MBTL1HDAC1 | |
| SCHEMBL434582 | 0.89 | CDK1 (0.43) | HDAC1HDAC2HDAC8YTHDC1CDK1 | |
| SCHEMBL434638 | 0.84 | TLR7 (0.36) | HTTMEN1KMT2AL3MBTL1DOT1L | |
| SCHEMBL13074311 | 0.83 | TLR7 (0.37) | MEN1KMT2AL3MBTL1HDAC1HDAC2 | |
| SCHEMBL10076900 | 0.81 | HTT (0.42) | HTTMEN1KMT2AL3MBTL1HDAC1 | |
| SCHEMBL13074313 | 0.81 | CCNE2 (0.36) | MEN1KMT2AL3MBTL1HDAC1HDAC2 | |
| SCHEMBL10077229 | 0.81 | TLR7 (0.37) | MEN1KMT2AL3MBTL1HDAC1DOT1L | |
| SCHEMBL10077231 | 0.79 | TSHR (0.43) | HTTHDAC1HDAC2SMN1; SMN2HDAC8 | |
| SCHEMBL7852208 | 0.78 | HDAC1 (0.43) | HDAC1HDAC2HDAC8HDAC6CDK1 | |
| SCHEMBL13074308 | 0.78 | CDK1 (0.42) | HDAC1HDAC2SMN1; SMN2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
| US-20100284959-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENE ARREST LTD. (IL) | 2010-11-11 | — | — | US | disclosed |
| US-20100284959-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENE ARREST LTD. (IL) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284959-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLRMT, POLM, SNRPE | HTT 1883/4885MEN1 4592/4885KMT2A 2479/4885 |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLM, POLRMT, DDB1 | HTT 1629/4885MEN1 4509/4885KMT2A 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.